Our lead program, NRM-823, is a T cell engager with tumor-specific targeting being developed for the treatment of multiple solid tumors and is currently in Phase 1 clinical studies in solid tumors. Our preclinical data demonstrate in vitro picomolar cell-killing and efficacy in transgenic mouse models of several cancers with no downregulation of surface protein expression. We anticipate this target may be leveraged in other biologics modalities including antibody-drug conjugates and radiopharmaceuticals.
NRM-823 is the first in a pipeline of biologic medicines that leverage Immuno-smart targets at the interface between the immune system and cancer, taking advantage of tumor specific characteristics and development opportunities for multiple modalities. Our anti-cancer medicines include therapeutic antibodies, bispecific antibodies, and payload-carrying biologics. Through our ongoing collaboration with the Lieping Chen lab, we have a product engine for continually evaluating and identifying promising anti-cancer targets.
